Findings published in Science Immunology resolve how human LAG-3 binds to its main ligand providing a better foundation for ...

Immutep Limited Findings published in Science Immunology resolve how human LAG-3 binds to its main ligand providing a better foundation for development of blocking LAG-3 therapeutics, including ...

SYDNEY, AUSTRALIA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology ...

Immutep Ltd (NASDAQ:IMMP), a biotechnology company specializing in pharmaceutical preparations with a market capitalization of $311 million, has announced the commencement of its TACTI-004 Phase ...

Findings published in Science Immunology resolve how human LAG-3 binds to its main ligand providing a better foundation for development of blocking LAG-3 therapeutics, including Immutep’s anti ...

Immutep (IMMP) announces new findings published in Science Immunology that resolve how human lymphocyte activation gene 3 binds to its main ligand MHC Class II, also known as HLA Class II in humans.

Favourable safety profile for world’s first LAG-3 agonist, IMP761, with no treatment related adverse events to dateAdditional ...

Immutep Ltd (NASDAQ:IMMP), a biotechnology company specializing in pharmaceutical preparations with a market capitalization of $311 million, has announced the commencement of its TACTI-004 Phase III ...

SYDNEY, AUSTRALIA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 ...